Standard
Liraglutide decreases postprandial fibroblast growth factor 19 and glucagon-like peptide 2, and increases postprandial cholecystokinin in individuals with obesity. / Bronden, A.; Nerild, H. H.; Nexoe-Larsen, C. C.; Hellmann, P. H.; Baekdal, M.; Gether, I. M.; Gillum, M. P.; Hartmann, B.; Knudsen, L. B.; Jacobsen, L. V.; Rehfeld, J. F.; Holst, J. J.; Vilsboll, T.; Sonne, D. P.; Knop, F. K.
I:
Diabetologia, Bind 64, Nr. SUPPL 1, 177, 2021, s. 94-94.
Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift
Harvard
Bronden, A, Nerild, HH, Nexoe-Larsen, CC, Hellmann, PH, Baekdal, M, Gether, IM, Gillum, MP
, Hartmann, B, Knudsen, LB, Jacobsen, LV
, Rehfeld, JF, Holst, JJ, Vilsboll, T, Sonne, DP
& Knop, FK 2021, '
Liraglutide decreases postprandial fibroblast growth factor 19 and glucagon-like peptide 2, and increases postprandial cholecystokinin in individuals with obesity',
Diabetologia, bind 64, nr. SUPPL 1, 177, s. 94-94.
https://doi.org/10.1007/s00125-021-05519-yAPA
Bronden, A., Nerild, H. H., Nexoe-Larsen, C. C., Hellmann, P. H., Baekdal, M., Gether, I. M., Gillum, M. P.
, Hartmann, B., Knudsen, L. B., Jacobsen, L. V.
, Rehfeld, J. F., Holst, J. J., Vilsboll, T., Sonne, D. P.
, & Knop, F. K. (2021).
Liraglutide decreases postprandial fibroblast growth factor 19 and glucagon-like peptide 2, and increases postprandial cholecystokinin in individuals with obesity.
Diabetologia,
64(SUPPL 1), 94-94. [177].
https://doi.org/10.1007/s00125-021-05519-yVancouver
Bronden A, Nerild HH, Nexoe-Larsen CC, Hellmann PH, Baekdal M, Gether IM o.a.
Liraglutide decreases postprandial fibroblast growth factor 19 and glucagon-like peptide 2, and increases postprandial cholecystokinin in individuals with obesity.
Diabetologia. 2021;64(SUPPL 1):94-94. 177.
https://doi.org/10.1007/s00125-021-05519-yAuthor
Bronden, A. ; Nerild, H. H. ; Nexoe-Larsen, C. C. ; Hellmann, P. H. ; Baekdal, M. ; Gether, I. M. ; Gillum, M. P. ; Hartmann, B. ; Knudsen, L. B. ; Jacobsen, L. V. ; Rehfeld, J. F. ; Holst, J. J. ; Vilsboll, T. ; Sonne, D. P. ; Knop, F. K. / Liraglutide decreases postprandial fibroblast growth factor 19 and glucagon-like peptide 2, and increases postprandial cholecystokinin in individuals with obesity. I: Diabetologia. 2021 ; Bind 64, Nr. SUPPL 1. s. 94-94.
Bibtex
@article{5c4e129a04d1473fa251feb35952492b,
title = "Liraglutide decreases postprandial fibroblast growth factor 19 and glucagon-like peptide 2, and increases postprandial cholecystokinin in individuals with obesity",
author = "A. Bronden and Nerild, {H. H.} and Nexoe-Larsen, {C. C.} and Hellmann, {P. H.} and M. Baekdal and Gether, {I. M.} and Gillum, {M. P.} and B. Hartmann and Knudsen, {L. B.} and Jacobsen, {L. V.} and Rehfeld, {J. F.} and Holst, {J. J.} and T. Vilsboll and Sonne, {D. P.} and Knop, {F. K.}",
year = "2021",
doi = "10.1007/s00125-021-05519-y",
language = "English",
volume = "64",
pages = "94--94",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer",
number = "SUPPL 1",
}
RIS
TY - ABST
T1 - Liraglutide decreases postprandial fibroblast growth factor 19 and glucagon-like peptide 2, and increases postprandial cholecystokinin in individuals with obesity
AU - Bronden, A.
AU - Nerild, H. H.
AU - Nexoe-Larsen, C. C.
AU - Hellmann, P. H.
AU - Baekdal, M.
AU - Gether, I. M.
AU - Gillum, M. P.
AU - Hartmann, B.
AU - Knudsen, L. B.
AU - Jacobsen, L. V.
AU - Rehfeld, J. F.
AU - Holst, J. J.
AU - Vilsboll, T.
AU - Sonne, D. P.
AU - Knop, F. K.
PY - 2021
Y1 - 2021
U2 - 10.1007/s00125-021-05519-y
DO - 10.1007/s00125-021-05519-y
M3 - Conference abstract in journal
C2 - 34468792
VL - 64
SP - 94
EP - 94
JO - Diabetologia
JF - Diabetologia
SN - 0012-186X
IS - SUPPL 1
M1 - 177
ER -
